The global hidradenitis suppurativa (HS) treatment market is expected to surpass an impressive valuation of US$ 763.6 million in 2023 and is projected to reach US$ 1,240.9 million by 2033, expected to register a CAGR of 4.97%.
Revenue growth of the global Hidradenitis suppurativa (HS) treatment market is significantly propelled by factors such as the increasing prevalence of chronic diseases, rapid advancements in the healthcare and medical sector, high adoption of the latest tools and techniques, and increasing funds by several public and private sectors.
In addition, growing focus on drug development, rising demand for precision medicine, high adoption of home care settings and point-of-care diagnostics, and growing investments in research and development activities are anticipated to drive global market revenue growth during the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 763.6 million |
| Anticipated Forecast Value (2033) | US$ 1240.9 million |
| Projected Growth Rate (2023 to 2033) | CAGR 4.97% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for Hidradenitis suppurativa (HS) treatment was worth US$ 640 million in 2018 while growing at a CAGR of 3.59% during the historical period.
InflaRx's lead drug candidate, vilobelimab (IFX-1), is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Hidradenitis suppurativa (HS) treatment (HS), a chronic debilitating systemic skin disease. The Company received scientific advice from the European Medicines Agency (EMA) about the European pathway for regulatory approval in July 2020. The Company is working diligently to address the feedback received from the agencies and analyzing the strategy for its Phase III development in HS.
Considering the arrival of new drugs and other factors, the industry of Hidradenitis suppurativa (HS) treatment is projected to grow at 4.97% CAGR, reaching USD 1240.9 million by end of the forecast period.
Adoption of pipeline therapies to propel market growth
Adoption of key Hidradenitis suppurativa (HS) treatment pipeline therapies such as Bermekimab (MABp1), IFX-1, INCB054707, Secukinumab, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody, Avacopan, Bimekizumab, and others are under different phases of clinical trials for Hidradenitis suppurativa (HS) treatment. Thus, leading to market expansion during the forecast period.
On the other hand, topline data from the AURORA Phase II clinical trial of Avacopan in Hidradenitis suppurativa (HS) treatment demonstrated a statistically significant higher response with avacopan at 30 mg BID than placebo in the pre-specified Hurley Stage III (severe) Hidradenitis suppurativa (HS) treatment patients, which will further drive market growth. Moreover, chemoCentryx plans to advance Avacopan into Phase III development for the treatment of patients with the most severe form of Hidradenitis suppurativa (HS) treatment. Thus, augmenting the market growth.
Also, Orismilast, Type 4 cyclic nucleotide phosphodiesterase inhibitors are being developed by Union Therapeutics for psoriasis, atopic dermatitis, and hidradenitis suppurative (HS) treatment which will fuel market expansion during the projected timeline.
Principal Consultant
High cost of treatment, delay in treatment restraining industry’s growth
The high cost associated with treatment is expected to challenge the growth of the market. Also, the dearth of healthcare infrastructure in developing economies and the delay in the procedure of treatment completion may be due to the unawareness of the disease to physicians. This will challenge the hidradenitis suppurativa (HS) treatment market. Additionally, the lack of skilled professionals and side effects involved with the treatment will act as restraints and further restrict the growth of the market during the forecast period.
North America dominates the market with the maximum share
The hidradenitis supportive treatment market in North America is expected to garner a valuation of US$ 620.4 million with a CAGR of 4.2% during the forecast period. Thus, accounting for 50% market share by end of the forecast period.
The growth is attributable to the surging adoption of newer techniques in this region and the growing presence of major key players and well-established healthcare infrastructure. Furthermore, growth is also driven by factors such as a rise in dermatological infections, an increase in clinical practices, and clinically trained professionals.
East Asia to drive growth at a Steady Pace
The market in East Asia is projected to grow at the fastest CAGR of 5.1% during the forecast period. Growth in the number of generic manufacturers and rising government initiatives in this region are propelling market growth. Also, the development of healthcare infrastructure will further fuel growth in this region.
The rise in inflammatory skin disease, healthcare awareness, and government support are leading to market expansion in this region. Additionally, continuous improvement in the life science industry and health services and the awareness of skin diseases and their treatment are factors contributing to the highest growth of this market. Moreover, increasing incomes and the purchasing power of citizens are witnessing a significant growth rate in this market which is benefitting the market in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Biologics propelling growth with maximum share
The biologics segment is expected to account for a share of 61.4% by the end of the forecast period. Humira (Abbvie) is the first and only approved drug for Moderate to Severe hidradenitis suppurativa (HS) treatment until now which will lead to the fastest acceleration of this segment. The growth of the biologics segment is augmented by rising demand for biologics due to high efficacy, rising product approvals, and the availability of a robust pipeline of biologic drugs for hidradenitis suppurative (HS) treatment.
For instance, In July 2015, the European Commission approved Humira to treat moderate to severe hidradenitis suppurative (HS) treatment. Similarly, this drug was approved in the USA in September 2015. Moreover, Humira is the only drug in Japan for hidradenitis suppurative (HS) treatment indication which will drive the growth of this segment in Japan. The unavailability of other alternative drugs and faster approval rate of other biologics similar to ‘Humira’ are expected to fuel the growth of this segment in the forecast period.
Another biologic, ‘Metformin’ is also used to treat metabolic syndrome associated with hidradenitis suppurative (HS) treatment and has been reported to reduce hidradenitis suppurativa (HS) treatment disease activity effectively. This will aid in the segment’s growth during the forecast period.
Hospital pharmacies lead the segment with a significant share
By distribution channel, the hospital pharmacies segment dominated the market in 2022, and this trend is projected to continue during the forecast period. This segment is anticipated to possess around 65% market share by end of 2033.
The growth is attributable to the rise in prices of drugs, rising income levels of poor & middle-class families, and faster approval of drugs. Moreover, an increasing number of initiatives from various governmental bodies in enhancing the infrastructure of hospitals and pharmacies are expected to boost the growth of the hospital pharmacies segment.
The topical route of administration driving growth with maximum share
This segment is anticipated to account for the maximum share of 68.5% by end of the forecast period. As topical medical yielded rapid and significant improvements in patients with moderate to severe hidradenitis suppurative (HS) treatment, it has witnessed higher demand in the hidradenitis suppurativa (HS) treatment market. This trend is most likely to remain the same during the forecast period.
The global Hidradenitis suppurativa (HS) treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are Inflarx, Novartis Pharmaceuticals, Incyte Corporation, UCB Biopharma SPRL, Janssen Pharmaceuticals, Amgen, Chemocentryx, Priovant Therapeutics/Pfizer, Anaptysbio, Abbvie, Acelyrin, Aclaris Therapeutics, Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, and Aristea Therapeutics.
Some recent developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 763.6 million |
| Market Value in 2033 | US$ 1,240.9 million |
| Growth Rate | CAGR of 4.97% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The regional market to witness an absolute growth opportunity of US$ 620.4 million through 2033.
The regional market in East Asia is projected to follow 5.1% growth rate until 2033.
High efficacy and increased product approvals have strengthened this segment.
The hospital pharmacies segment achieves around 65% of the global sales .
The topical route of administration to account for 68.5% of the global market share.
1. Executive Summary | Hidradenitis Suppurativa (HS) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Clinical Stages
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Clinical Stages, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Clinical Stages, 2023 to 2033
5.3.1. Hurley Stage 1- low
5.3.2. Hurley Stage 2-moderate
5.3.3. Hurley Stage 3-high
5.4. Y-o-Y Growth Trend Analysis By Clinical Stages, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Clinical Stages, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
6.3.1. Medication
6.3.1.1. Biologics
6.3.1.2. Antibiotics
6.3.1.3. Hormonal Therapy
6.3.1.4. Immune Suppurativa Drugs
6.3.1.5. Zinc Supplements
6.3.1.6. Pain Medications
6.3.2. Surgery
6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
7.3.1. Oral
7.3.2. Topical
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
8.3.1. Hospitals
8.3.2. Homecare
8.3.3. Specialty Clinics
8.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
9.3.1. Hospital Pharmacy
9.3.2. Online Pharmacy
9.3.3. Retail Pharmacy
9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
10.1. Introduction
10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. South Asia
10.3.5. East Asia
10.3.6. Oceania
10.3.7. Middle East & Africa
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. United States of America
11.2.1.2. Canada
11.2.2. By Clinical Stages
11.2.3. By Treatment Type
11.2.4. By Route of Administration
11.2.5. By End Users
11.2.6. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Clinical Stages
11.3.3. By Treatment Type
11.3.4. By Route of Administration
11.3.5. By End Users
11.3.6. By Distribution Channel
11.4. Key Takeaways
12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Brazil
12.2.1.2. Mexico
12.2.1.3. Rest of Latin America
12.2.2. By Clinical Stages
12.2.3. By Treatment Type
12.2.4. By Route of Administration
12.2.5. By End Users
12.2.6. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Clinical Stages
12.3.3. By Treatment Type
12.3.4. By Route of Administration
12.3.5. By End Users
12.3.6. By Distribution Channel
12.4. Key Takeaways
13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Germany
13.2.1.2. United Kingdom
13.2.1.3. France
13.2.1.4. Spain
13.2.1.5. Italy
13.2.1.6. Rest of Europe
13.2.2. By Clinical Stages
13.2.3. By Treatment Type
13.2.4. By Route of Administration
13.2.5. By End Users
13.2.6. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Clinical Stages
13.3.3. By Treatment Type
13.3.4. By Route of Administration
13.3.5. By End Users
13.3.6. By Distribution Channel
13.4. Key Takeaways
14. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Malaysia
14.2.1.3. Singapore
14.2.1.4. Thailand
14.2.1.5. Rest of South Asia
14.2.2. By Clinical Stages
14.2.3. By Treatment Type
14.2.4. By Route of Administration
14.2.5. By End Users
14.2.6. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Clinical Stages
14.3.3. By Treatment Type
14.3.4. By Route of Administration
14.3.5. By End Users
14.3.6. By Distribution Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Clinical Stages
15.2.3. By Treatment Type
15.2.4. By Route of Administration
15.2.5. By End Users
15.2.6. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Clinical Stages
15.3.3. By Treatment Type
15.3.4. By Route of Administration
15.3.5. By End Users
15.3.6. By Distribution Channel
15.4. Key Takeaways
16. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. Australia
16.2.1.2. New Zealand
16.2.2. By Clinical Stages
16.2.3. By Treatment Type
16.2.4. By Route of Administration
16.2.5. By End Users
16.2.6. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Clinical Stages
16.3.3. By Treatment Type
16.3.4. By Route of Administration
16.3.5. By End Users
16.3.6. By Distribution Channel
16.4. Key Takeaways
17. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
17.2.1. By Country
17.2.1.1. GCC Countries
17.2.1.2. South Africa
17.2.1.3. Israel
17.2.1.4. Rest of Middle East & Africa
17.2.2. By Clinical Stages
17.2.3. By Treatment Type
17.2.4. By Route of Administration
17.2.5. By End Users
17.2.6. By Distribution Channel
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Clinical Stages
17.3.3. By Treatment Type
17.3.4. By Route of Administration
17.3.5. By End Users
17.3.6. By Distribution Channel
17.4. Key Takeaways
18. Key Countries Market Analysis
18.1. United States of America
18.1.1. Pricing Analysis
18.1.2. Market Share Analysis, 2022
18.1.2.1. By Clinical Stages
18.1.2.2. By Treatment Type
18.1.2.3. By Route of Administration
18.1.2.4. By End Users
18.1.2.5. By Distribution Channel
18.2. Canada
18.2.1. Pricing Analysis
18.2.2. Market Share Analysis, 2022
18.2.2.1. By Clinical Stages
18.2.2.2. By Treatment Type
18.2.2.3. By Route of Administration
18.2.2.4. By End Users
18.2.2.5. By Distribution Channel
18.3. Brazil
18.3.1. Pricing Analysis
18.3.2. Market Share Analysis, 2022
18.3.2.1. By Clinical Stages
18.3.2.2. By Treatment Type
18.3.2.3. By Route of Administration
18.3.2.4. By End Users
18.3.2.5. By Distribution Channel
18.4. Mexico
18.4.1. Pricing Analysis
18.4.2. Market Share Analysis, 2022
18.4.2.1. By Clinical Stages
18.4.2.2. By Treatment Type
18.4.2.3. By Route of Administration
18.4.2.4. By End Users
18.4.2.5. By Distribution Channel
18.5. Germany
18.5.1. Pricing Analysis
18.5.2. Market Share Analysis, 2022
18.5.2.1. By Clinical Stages
18.5.2.2. By Treatment Type
18.5.2.3. By Route of Administration
18.5.2.4. By End Users
18.5.2.5. By Distribution Channel
18.6. United Kingdom
18.6.1. Pricing Analysis
18.6.2. Market Share Analysis, 2022
18.6.2.1. By Clinical Stages
18.6.2.2. By Treatment Type
18.6.2.3. By Route of Administration
18.6.2.4. By End Users
18.6.2.5. By Distribution Channel
18.7. France
18.7.1. Pricing Analysis
18.7.2. Market Share Analysis, 2022
18.7.2.1. By Clinical Stages
18.7.2.2. By Treatment Type
18.7.2.3. By Route of Administration
18.7.2.4. By End Users
18.7.2.5. By Distribution Channel
18.8. Spain
18.8.1. Pricing Analysis
18.8.2. Market Share Analysis, 2022
18.8.2.1. By Clinical Stages
18.8.2.2. By Treatment Type
18.8.2.3. By Route of Administration
18.8.2.4. By End Users
18.8.2.5. By Distribution Channel
18.9. Italy
18.9.1. Pricing Analysis
18.9.2. Market Share Analysis, 2022
18.9.2.1. By Clinical Stages
18.9.2.2. By Treatment Type
18.9.2.3. By Route of Administration
18.9.2.4. By End Users
18.9.2.5. By Distribution Channel
18.10. India
18.10.1. Pricing Analysis
18.10.2. Market Share Analysis, 2022
18.10.2.1. By Clinical Stages
18.10.2.2. By Treatment Type
18.10.2.3. By Route of Administration
18.10.2.4. By End Users
18.10.2.5. By Distribution Channel
18.11. Malaysia
18.11.1. Pricing Analysis
18.11.2. Market Share Analysis, 2022
18.11.2.1. By Clinical Stages
18.11.2.2. By Treatment Type
18.11.2.3. By Route of Administration
18.11.2.4. By End Users
18.11.2.5. By Distribution Channel
18.12. Singapore
18.12.1. Pricing Analysis
18.12.2. Market Share Analysis, 2022
18.12.2.1. By Clinical Stages
18.12.2.2. By Treatment Type
18.12.2.3. By Route of Administration
18.12.2.4. By End Users
18.12.2.5. By Distribution Channel
18.13. Thailand
18.13.1. Pricing Analysis
18.13.2. Market Share Analysis, 2022
18.13.2.1. By Clinical Stages
18.13.2.2. By Treatment Type
18.13.2.3. By Route of Administration
18.13.2.4. By End Users
18.13.2.5. By Distribution Channel
18.14. China
18.14.1. Pricing Analysis
18.14.2. Market Share Analysis, 2022
18.14.2.1. By Clinical Stages
18.14.2.2. By Treatment Type
18.14.2.3. By Route of Administration
18.14.2.4. By End Users
18.14.2.5. By Distribution Channel
18.15. Japan
18.15.1. Pricing Analysis
18.15.2. Market Share Analysis, 2022
18.15.2.1. By Clinical Stages
18.15.2.2. By Treatment Type
18.15.2.3. By Route of Administration
18.15.2.4. By End Users
18.15.2.5. By Distribution Channel
18.16. South Korea
18.16.1. Pricing Analysis
18.16.2. Market Share Analysis, 2022
18.16.2.1. By Clinical Stages
18.16.2.2. By Treatment Type
18.16.2.3. By Route of Administration
18.16.2.4. By End Users
18.16.2.5. By Distribution Channel
18.17. Australia
18.17.1. Pricing Analysis
18.17.2. Market Share Analysis, 2022
18.17.2.1. By Clinical Stages
18.17.2.2. By Treatment Type
18.17.2.3. By Route of Administration
18.17.2.4. By End Users
18.17.2.5. By Distribution Channel
18.18. New Zealand
18.18.1. Pricing Analysis
18.18.2. Market Share Analysis, 2022
18.18.2.1. By Clinical Stages
18.18.2.2. By Treatment Type
18.18.2.3. By Route of Administration
18.18.2.4. By End Users
18.18.2.5. By Distribution Channel
18.19. GCC Countries
18.19.1. Pricing Analysis
18.19.2. Market Share Analysis, 2022
18.19.2.1. By Clinical Stages
18.19.2.2. By Treatment Type
18.19.2.3. By Route of Administration
18.19.2.4. By End Users
18.19.2.5. By Distribution Channel
18.20. South Africa
18.20.1. Pricing Analysis
18.20.2. Market Share Analysis, 2022
18.20.2.1. By Clinical Stages
18.20.2.2. By Treatment Type
18.20.2.3. By Route of Administration
18.20.2.4. By End Users
18.20.2.5. By Distribution Channel
18.21. Israel
18.21.1. Pricing Analysis
18.21.2. Market Share Analysis, 2022
18.21.2.1. By Clinical Stages
18.21.2.2. By Treatment Type
18.21.2.3. By Route of Administration
18.21.2.4. By End Users
18.21.2.5. By Distribution Channel
19. Market Structure Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Market Share Analysis of Top Players
19.3.1. By Regional
19.3.2. By Clinical Stages
19.3.3. By Treatment Type
19.3.4. By Route of Administration
19.3.5. By End Users
19.3.6. By Distribution Channel
20. Competition Analysis
20.1. Competition Deep Dive
20.1.1. InFlaRx N.V
20.1.1.1. Overview
20.1.1.2. Product Portfolio
20.1.1.3. Profitability by Market Segments
20.1.1.4. Sales Footprint
20.1.1.5. Strategy Overview
20.1.1.5.1. Marketing Strategy
20.1.2. Novartis A.G.
20.1.2.1. Overview
20.1.2.2. Product Portfolio
20.1.2.3. Profitability by Market Segments
20.1.2.4. Sales Footprint
20.1.2.5. Strategy Overview
20.1.2.5.1. Marketing Strategy
20.1.3. Incyte Corporation
20.1.3.1. Overview
20.1.3.2. Product Portfolio
20.1.3.3. Profitability by Market Segments
20.1.3.4. Sales Footprint
20.1.3.5. Strategy Overview
20.1.3.5.1. Marketing Strategy
20.1.4. UCB Biopharma SPRL
20.1.4.1. Overview
20.1.4.2. Product Portfolio
20.1.4.3. Profitability by Market Segments
20.1.4.4. Sales Footprint
20.1.4.5. Strategy Overview
20.1.4.5.1. Marketing Strategy
20.1.5. Janssen Pharmaceuticals
20.1.5.1. Overview
20.1.5.2. Product Portfolio
20.1.5.3. Profitability by Market Segments
20.1.5.4. Sales Footprint
20.1.5.5. Strategy Overview
20.1.5.5.1. Marketing Strategy
20.1.6. Amgen Inc.
20.1.6.1. Overview
20.1.6.2. Product Portfolio
20.1.6.3. Profitability by Market Segments
20.1.6.4. Sales Footprint
20.1.6.5. Strategy Overview
20.1.6.5.1. Marketing Strategy
20.1.7. ChemoCentryx
20.1.7.1. Overview
20.1.7.2. Product Portfolio
20.1.7.3. Profitability by Market Segments
20.1.7.4. Sales Footprint
20.1.7.5. Strategy Overview
20.1.7.5.1. Marketing Strategy
20.1.8. Priovant Therapeutics
20.1.8.1. Overview
20.1.8.2. Product Portfolio
20.1.8.3. Profitability by Market Segments
20.1.8.4. Sales Footprint
20.1.8.5. Strategy Overview
20.1.8.5.1. Marketing Strategy
20.1.9. AnaptysBio
20.1.9.1. Overview
20.1.9.2. Product Portfolio
20.1.9.3. Profitability by Market Segments
20.1.9.4. Sales Footprint
20.1.9.5. Strategy Overview
20.1.9.5.1. Marketing Strategy
20.1.10. AbbVie Inc.
20.1.10.1. Overview
20.1.10.2. Product Portfolio
20.1.10.3. Profitability by Market Segments
20.1.10.4. Sales Footprint
20.1.10.5. Strategy Overview
20.1.10.5.1. Marketing Strategy
20.1.11. ACELYRIN
20.1.11.1. Overview
20.1.11.2. Product Portfolio
20.1.11.3. Profitability by Market Segments
20.1.11.4. Sales Footprint
20.1.11.5. Strategy Overview
20.1.11.5.1. Marketing Strategy
20.1.12. Aclaris Therapeutics Inc.
20.1.12.1. Overview
20.1.12.2. Product Portfolio
20.1.12.3. Profitability by Market Segments
20.1.12.4. Sales Footprint
20.1.12.5. Strategy Overview
20.1.12.5.1. Marketing Strategy
20.1.13. Boehringer Ingelheim
20.1.13.1. Overview
20.1.13.2. Product Portfolio
20.1.13.3. Profitability by Market Segments
20.1.13.4. Sales Footprint
20.1.13.5. Strategy Overview
20.1.13.5.1. Marketing Strategy
20.1.14. Eli Lilly & Company
20.1.14.1. Overview
20.1.14.2. Product Portfolio
20.1.14.3. Profitability by Market Segments
20.1.14.4. Sales Footprint
20.1.14.5. Strategy Overview
20.1.14.5.1. Marketing Strategy
20.1.15. MoonLake Immunotherapeutics
20.1.15.1. Overview
20.1.15.2. Product Portfolio
20.1.15.3. Profitability by Market Segments
20.1.15.4. Sales Footprint
20.1.15.5. Strategy Overview
20.1.15.5.1. Marketing Strategy
20.1.16. Aristea Therapeutics
20.1.16.1. Overview
20.1.16.2. Product Portfolio
20.1.16.3. Profitability by Market Segments
20.1.16.4. Sales Footprint
20.1.16.5. Strategy Overview
20.1.16.5.1. Marketing Strategy
21. Assumptions & Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Hidradenitis Suppurativa (HS) Treatment Market
